Sellas Life Sciences is trading 4.27% down at $12.77, broadly in line with the biotechnology sector, which is down 4.24% during the regular session.
- No new company-specific announcement dated September 1, 2026, was identified; latest reported update: August 11 second-quarter release.
- Investors remain focused on the pending REGAL trial readout.
- Major U.S. indexes are lower amid renewed inflation, interest-rate, geopolitical and global bond-market concerns; evidence points primarily to sector and market pressure, not a fresh Sellas-specific catalyst.